{
  "actions": [
    {
      "acted_at": "2019-12-11", 
      "action_code": "Intro-H", 
      "references": [], 
      "text": "Introduced in House", 
      "type": "action"
    }, 
    {
      "acted_at": "2019-12-11", 
      "action_code": "H11100", 
      "committees": [
        "HSWM"
      ], 
      "references": [], 
      "status": "REFERRED", 
      "text": "Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.", 
      "type": "referral"
    }, 
    {
      "acted_at": "2019-12-11", 
      "action_code": "H11100", 
      "committees": [
        "HSIF"
      ], 
      "references": [], 
      "text": "Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.", 
      "type": "referral"
    }, 
    {
      "acted_at": "2019-12-12", 
      "action_code": "", 
      "committees": [
        "HSIF"
      ], 
      "references": [], 
      "text": "Referred to the Subcommittee on Health.", 
      "type": "referral"
    }
  ], 
  "amendments": [], 
  "bill_id": "hr5402-116", 
  "bill_type": "hr", 
  "by_request": false, 
  "committee_reports": [], 
  "committees": [
    {
      "activity": [
        "referral"
      ], 
      "committee": "House Energy and Commerce", 
      "committee_id": "HSIF"
    }, 
    {
      "activity": [
        "referral"
      ], 
      "committee": "House Energy and Commerce", 
      "committee_id": "HSIF", 
      "subcommittee": "Subcommittee on Health", 
      "subcommittee_id": "14"
    }, 
    {
      "activity": [
        "referral"
      ], 
      "committee": "House Ways and Means", 
      "committee_id": "HSWM"
    }
  ], 
  "congress": "116", 
  "cosponsors": [
    {
      "bioguide_id": "F000466", 
      "district": "1", 
      "name": "Fitzpatrick, Brian K.", 
      "original_cosponsor": false, 
      "sponsored_at": "2019-12-18", 
      "state": "PA", 
      "title": "Rep", 
      "withdrawn_at": null
    }, 
    {
      "bioguide_id": "U000031", 
      "district": "6", 
      "name": "Upton, Fred", 
      "original_cosponsor": true, 
      "sponsored_at": "2019-12-11", 
      "state": "MI", 
      "title": "Rep", 
      "withdrawn_at": null
    }
  ], 
  "enacted_as": null, 
  "history": {
    "active": false, 
    "awaiting_signature": false, 
    "enacted": false, 
    "vetoed": false
  }, 
  "introduced_at": "2019-12-11", 
  "number": "5402", 
  "official_title": "To direct the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to conduct a study on high-risk, high-reward drugs, and for other purposes.", 
  "popular_title": null, 
  "related_bills": [], 
  "short_title": "Protecting America\u2019s Life Saving Medicines Act of 2019", 
  "sponsor": {
    "bioguide_id": "G000583", 
    "district": "5", 
    "name": "Gottheimer, Josh", 
    "state": "NJ", 
    "title": "Rep", 
    "type": "person"
  }, 
  "status": "REFERRED", 
  "status_at": "2019-12-11", 
  "subjects": [
    "Drug safety, medical device, and laboratory regulation", 
    "Drug therapy", 
    "Government studies and investigations", 
    "Income tax credits", 
    "Medical research", 
    "Taxation"
  ], 
  "subjects_top_term": "Taxation", 
  "summary": {
    "as": "Introduced in House", 
    "date": "2019-12-11T05:00:00Z", 
    "text": "Protecting America's Life Saving Medicines Act of 2019\n\nThis bill directs the Food and Drug Administration (FDA) to conduct a study on drugs that are currently being tested and are unlikely to be approved, but would, if approved, address an unmet medical need for the treatment of a serious or life threatening disease or condition or a rare disease or condition (high-risk, high-reward drugs). The FDA must submit to the Department of the Treasury a list of such high-risk, high-reward drugs not later than 180 days after the completion of the study.\n\nThe bill also allows a new tax credit for 25% of the clinical testing expenses for high-risk, high-reward drugs."
  }, 
  "titles": [
    {
      "as": null, 
      "is_for_portion": false, 
      "title": "Protecting America\u2019s Life Saving Medicines Act of 2019", 
      "type": "display"
    }, 
    {
      "as": "introduced", 
      "is_for_portion": false, 
      "title": "Protecting America\u2019s Life Saving Medicines Act of 2019", 
      "type": "short"
    }, 
    {
      "as": "introduced", 
      "is_for_portion": false, 
      "title": "To direct the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to conduct a study on high-risk, high-reward drugs, and for other purposes.", 
      "type": "official"
    }
  ], 
  "updated_at": "2020-12-28T22:31:28Z", 
  "url": "https://www.govinfo.gov/bulkdata/BILLSTATUS/116/hr/BILLSTATUS-116hr5402.xml"
}